Contrasting molecular and pharmacodynamic signatures of response and resistance to sequential bortezomib and temozolomide in recurrent IDH-wildtype glioblastoma and grade 4 IDH-mutant astrocytoma: an exploratory interim analysis of NCT03643549 phase IB/II trial

Dorota Goplen, Mohummad Aminur Rahman, Jorunn Brekke, Andreas Waha, Leif Oltedal, Judit Haasz, Surendra Kumar, Even Birkeland, Frode Selheim, Stein Atle Lie, Martha Chekenya

Open source

DOI: 10.1186/s40364-026-01023-w
Published: 2026-10-27
Container: Biomarker Research
Publisher: Springer Science and Business Media LLC
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1186/s40364-026-01023-w,
  title = {Contrasting molecular and pharmacodynamic signatures of response and resistance to sequential bortezomib and temozolomide in recurrent IDH-wildtype glioblastoma and grade 4 IDH-mutant astrocytoma: an exploratory interim analysis of NCT03643549 phase IB/II trial},
  author = {Dorota Goplen and Mohummad Aminur Rahman and Jorunn Brekke and Andreas Waha and Leif Oltedal and Judit Haasz and Surendra Kumar and Even Birkeland and Frode Selheim and Stein Atle Lie and Martha Chekenya},
  year = {2026},
  journal = {Biomarker Research},
  doi = {10.1186/s40364-026-01023-w},
  url = {https://doi.org/10.1186/s40364-026-01023-w}
}

RIS

TY  - JOUR
TI  - Contrasting molecular and pharmacodynamic signatures of response and resistance to sequential bortezomib and temozolomide in recurrent IDH-wildtype glioblastoma and grade 4 IDH-mutant astrocytoma: an exploratory interim analysis of NCT03643549 phase IB/II trial
AU  - Dorota Goplen
AU  - Mohummad Aminur Rahman
AU  - Jorunn Brekke
AU  - Andreas Waha
AU  - Leif Oltedal
AU  - Judit Haasz
AU  - Surendra Kumar
AU  - Even Birkeland
AU  - Frode Selheim
AU  - Stein Atle Lie
AU  - Martha Chekenya
PY  - 2026
JO  - Biomarker Research
DO  - 10.1186/s40364-026-01023-w
UR  - https://doi.org/10.1186/s40364-026-01023-w
ER  -

APA

Goplen, D., Rahman, M. A., Brekke, J., Waha, A., Oltedal, L., Haasz, J., Kumar, S., Birkeland, E., Selheim, F., Lie, S. A., & Chekenya, M. (2026). Contrasting molecular and pharmacodynamic signatures of response and resistance to sequential bortezomib and temozolomide in recurrent IDH-wildtype glioblastoma and grade 4 IDH-mutant astrocytoma: an exploratory interim analysis of NCT03643549 phase IB/II trial. Biomarker Research. https://doi.org/10.1186/s40364-026-01023-w

Source records

crossref · retrieved 2026-11-10T14:32:33.188Z